Cargando…
Uncovering Novel Pre-Treatment Molecular Biomarkers for Anti-TNF Therapeutic Response in Patients with Crohn’s Disease
Neutralising monoclonal antibodies for tumour necrosis factor (TNF) has been widely used to treat Crohn’s disease (CD) in clinical practice. However, differential individual response necessitates a therapeutic response assessment of anti-TNF agents in CD patients for optimizing therapeutic strategy....
Autores principales: | Kwak, Min Seob, Cha, Jae Myung, Jeon, Jung Won, Yoon, Jin Young, Park, Su Bee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036297/ https://www.ncbi.nlm.nih.gov/pubmed/35466218 http://dx.doi.org/10.3390/jfb13020036 |
Ejemplares similares
-
Single-Cell Network-Based Drug Repositioning for Discovery of Therapies against Anti-Tumour Necrosis Factor-Resistant Crohn’s Disease
por: Kwak, Min Seob, et al.
Publicado: (2023) -
Development of a Novel Metagenomic Biomarker for Prediction of Upper Gastrointestinal Tract Involvement in Patients With Crohn’s Disease
por: Kwak, Min Seob, et al.
Publicado: (2020) -
Novel candidate drugs in anti-tumor necrosis factor refractory Crohn’s diseases: in silico study for drug repositioning
por: Kwak, Min Seob, et al.
Publicado: (2020) -
Chasm between Public Perceptions and Epidemiological Data on Colorectal Cancer
por: Park, Su Bee, et al.
Publicado: (2023) -
Practical strategy for optimizing the timing of anti-tumor necrosis factor-α therapy in Crohn disease: A nationwide population-based study
por: Kwak, Min Seob, et al.
Publicado: (2020)